Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

S1800000

Sulfadiazine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

4-Amino-N-(2-pyrimidinyl)benzenesulfonamide, N1-(Pyrimidin-2-yl)sulfanilamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C10H10N4O2S
Numéro CAS:
68-35-9
Poids moléculaire :
250.28
Numéro Beilstein :
6733588
Numéro MDL:
MFCD00006065
Code UNSPSC :
41116107
ID de substance PubChem :
329824490
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

sulfadiazine

Fabricant/nom de marque

EDQM

Pf

253 °C (dec.) (lit.)

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

Nc1ccc(cc1)S(=O)(=O)Nc2ncccn2

InChI

1S/C10H10N4O2S/c11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10/h1-7H,11H2,(H,12,13,14)

Clé InChI

SEEPANYCNGTZFQ-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Sulfadiazine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1625009

Sulfadiazine, United States Pharmacopeia (USP) Reference Standard

1633506

Sulfanilic acid, United States Pharmacopeia (USP) Reference Standard

1612608

Silver sulfadiazine, United States Pharmacopeia (USP) Reference Standard

Y0001469

Sulfadiazine impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001480

Sulfadiazine, European Pharmacopoeia (EP) Reference Standard

Y0001462

Acetylsulfadiazine, European Pharmacopoeia (EP) Reference Standard

PHR1419

Sulfanilic Acid, Pharmaceutical Secondary Standard; Certified Reference Material

BP312

Sulfadiazine, British Pharmacopoeia (BP) Reference Standard

PHR2654

Silver Sulfadiazine, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogrammes

Health hazardExclamation markEnvironment
GHS08,GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H361d,H411

Classification des risques

Acute Tox. 4 Oral - Aquatic Chronic 2 - Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

U Kronawitter et al.
Deutsche medizinische Wochenschrift (1946), 118(46), 1683-1686 (1993-11-19)
A 45-year-old man with AIDS was treated for a recurrence of cerebral toxoplasmosis with sulphadiazine, 4 g, and pyrimethamine, 75 mg, daily. Owing to a lack of appetite and dysphagia he drank rather little water during the first week of
Charlotte Catalano-Pons et al.
Pediatric nephrology (Berlin, Germany), 19(8), 928-931 (2004-06-19)
Sulfadiazine-associated urinary calculi have been described in HIV-positive adult patients but rarely in children. We report two pediatric cases of sulfadiazine-induced nephrolithiasis and review 45 adult cases from the literature. One had a hyper-IgM syndrome and was treated with sulfadiazine
D I Simon et al.
Archives of internal medicine, 150(11), 2379-2384 (1990-11-01)
Toxoplasma gondii encephalitis is an important opportunistic infection in the acquired immunodeficiency syndrome, estimated to occur in 20,000 to 40,000 patients with acquired immunodeficiency syndrome in the United States by 1991. The combination of sulfadiazine and pyrimethamine is regarded as
S Hoffmann
Scandinavian journal of plastic and reconstructive surgery, 18(1), 119-126 (1984-01-01)
Topical antibacterial treatment is of major importance in the burn patient. Silver sulfadiazine is an effective agent with low toxicity and few side effects. Deposition of silver in tissues, and absorption of sulfadiazine are both minimal. Present and future problems
L M Upton et al.
Antimicrobial agents and chemotherapy, 59(1), 490-497 (2014-11-12)
To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which fail to measure the single crucial
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique